Loading
A phase 1/2 trial of Nivolumab in ovarian cancer and non-small-cell lung cancer, run by BicycleTx Limited, active and no longer recruiting.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression is a phase 1/2 interventional study registered as NCT04180371 by BicycleTx Limited, with 288 participants planned, started 2019-11-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: BT5528, Nivolumab. Conditions listed: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Bicycle Therapeutics, Nivolumab, Immune checkpoint inhibitors.
Shares Bicycle Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Bicycle Therapeutics, Ovarian cancer, Non-small-cell lung cancer.